Karolinska Development portfolio company OssDsign announces new European partnerships for commercialization of novel medical implants
(Thomson Reuters ONE) -
STOCKHOLM - January 12, 2017 Karolinska Development AB (Nasdaq Stockholm: KDEV)
today announces that portfolio company OssDsign AB, a Swedish designer,
manufacturer and distributor of next generation implants for cranial and facial
reconstruction, has entered new commercial partnerships covering distribution of
its products in Italy, Spain, Switzerland, Austria and The Netherlands.
Details from the OssDsign announcement follow:
OssDsign's lead products - OSSDSIGN® Cranial and OSSDSIGN® Facial - are already
on sale in Germany, the UK and the Nordic region, as well as selected non-
European markets including Singapore and Israel. The Company is preparing for
its first product launch in the US, which is anticipated during the first
quarter of 2017, and is also undertaking regulatory and commercial activities in
Japan.
OssDsign commercial strategy is focused on building sales of its innovative
products through a combination of internal sales organisation and distribution
partnerships.
Anders Lundqvist, CEO of OssDsign, said: "We are very pleased to increase our
commercial footprint in Europe as we work to become the leading provider of
regenerative implants for cranial and facial reconstruction. We now have
experienced and well-motivated teams in place in order to execute our European
strategy and bring OssDsign products closer to the surgeons and patients who
will ultimately benefit from them."
Viktor Drvota, Chief Investment Officer at Karolinska Development, said: "These
partnerships are positive news for OssDsign, as the Company continues to execute
its commercial strategy and drive sales of its innovative product around the
world."
For further information, please contact:
Jim Van heusden, CEO, Karolinska Development AB
Phone: +46 72 858 32 09, e-mail: jim.van.heusden(at)karolinskadevelopment.com
Christian Tange, CFO, Karolinska Development AB
Phone: +46 73 712 14 30, e-mail: christian.tange(at)karolinskadevelopment.com
David Dible/Mark Swallow/Pip Batty, Citigate Dewe Rogerson
Phone: +44 20 7638 9571; e-mail: KDev(at)citigatedr.co.uk
TO THE EDITORS
About OssDsign AB
OssDsign is a Swedish medtech company dedicated to creating regenerative
implants for improved healing of bone defects and deficits in skull, facial and
other types of surgery. OssDsign has successfully launched its first patient
specific products OSSDSIGN® Cranial and OSSDSIGN® Facial in Germany, the UK and
the Nordic countries, and further global market expansion is ongoing.
By combining clinical insight with proprietary material technology and patient
adapted design, OssDsign supplies an expanding range of tailored solutions for
cranial repair and facial bone reconstruction. OssDsign's technology is the
result of collaboration between clinical researchers at the Karolinska
University Hospital, Stockholm, and material science experts at the Ångström
Laboratory at Uppsala University. Main investors in OssDsign are Karolinska
Development, SEB Venture Capital, Fouriertransform and Almi Invest. For more
information visit www.ossdsign.com
About Karolinska Development AB
Karolinska Development AB is an investment company focused on identifying
medical innovation and investing in the creation and growth of companies
developing these assets into differentiated products that will make a difference
to patients' lives and provide an attractive return on investment.
Karolinska Development has access to world-class medical innovations at the
Karolinska Institutet and other leading universities and research institutes in
the Nordic region. The Company aims to build companies around scientists who are
leaders in their fields, supported by experienced management teams and advisers,
and co-funded by specialist international investors, to provide the greatest
chance of success.
Karolinska Development has established a portfolio of 12 companies targeting
opportunities in innovative treatment for life-threatening or serious
debilitating diseases.
The Company is led by a team including investment professionals with strong
venture capital backgrounds, experienced company builders and entrepreneurs,
with access to a strong global network. For more information, please
visit www.karolinskadevelopment.com
OssDsign Partnership:
http://hugin.info/143071/R/2070726/778039.pdf
This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Karolinska Development AB (publ) via GlobeNewswire
Unternehmensinformation / Kurzprofil:
Datum: 12.01.2017 - 08:00 Uhr
Sprache: Deutsch
News-ID 517180
Anzahl Zeichen: 5420
contact information:
Town:
Solna
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 180 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"Karolinska Development portfolio company OssDsign announces new European partnerships for commercialization of novel medical implants"
steht unter der journalistisch-redaktionellen Verantwortung von
Karolinska Development AB (publ) (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
